Literature DB >> 28480899

Immunosuppressive cell death in cancer.

Jiajie Hou1, Tim F Greten2, Qiang Xia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28480899      PMCID： PMC6309557          DOI： 10.1038/nri.2017.46

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  15 in total

1.  A CXCL1 paracrine network links cancer chemoresistance and metastasis.

Authors:  Swarnali Acharyya; Thordur Oskarsson; Sakari Vanharanta; Srinivas Malladi; Juliet Kim; Patrick G Morris; Katia Manova-Todorova; Margaret Leversha; Nancy Hogg; Venkatraman E Seshan; Larry Norton; Edi Brogi; Joan Massagué
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

Review 2.  Interleukin 1α and the inflammatory process.

Authors:  Nelson C Di Paolo; Dmitry M Shayakhmetov
Journal:  Nat Immunol       Date:  2016-07-19       Impact factor: 25.606

Review 3.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

4.  Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9.

Authors:  Yao Liu; Wei Yan; Samer Tohme; Man Chen; Yu Fu; Dean Tian; Michael Lotze; Daolin Tang; Allan Tsung
Journal:  J Hepatol       Date:  2015-02-12       Impact factor: 25.083

Review 5.  The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review.

Authors:  Colin H Richards; Zahra Mohammed; Tahir Qayyum; Paul G Horgan; Donald C McMillan
Journal:  Future Oncol       Date:  2011-10       Impact factor: 3.404

6.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

Authors:  Olivier De Henau; Matthew Rausch; David Winkler; Luis Felipe Campesato; Cailian Liu; Daniel Hirschhorn Cymerman; Sadna Budhu; Arnab Ghosh; Melissa Pink; Jeremy Tchaicha; Mark Douglas; Thomas Tibbitts; Sujata Sharma; Jennifer Proctor; Nicole Kosmider; Kerry White; Howard Stern; John Soglia; Julian Adams; Vito J Palombella; Karen McGovern; Jeffery L Kutok; Jedd D Wolchok; Taha Merghoub
Journal:  Nature       Date:  2016-11-09       Impact factor: 49.962

7.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

Authors:  David S Hong; David Hui; Eduardo Bruera; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
Journal:  Lancet Oncol       Date:  2014-04-17       Impact factor: 41.316

8.  IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Authors:  Kelly Kersten; Chris W Doornebal; Seth B Coffelt; Jorieke Weiden; Kim Vrijland; Cheei-Sing Hau; Niels J M Verstegen; Metamia Ciampricotti; Lukas J A C Hawinkels; Jos Jonkers; Karin E de Visser
Journal:  Nature       Date:  2015-03-30       Impact factor: 49.962

9.  The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.

Authors:  Lena Seifert; Gregor Werba; Shaun Tiwari; Nancy Ngoc Giao Ly; Sara Alothman; Dalia Alqunaibit; Antonina Avanzi; Rocky Barilla; Donnele Daley; Stephanie H Greco; Alejandro Torres-Hernandez; Matthew Pergamo; Atsuo Ochi; Constantinos P Zambirinis; Mridul Pansari; Mauricio Rendon; Daniel Tippens; Mautin Hundeyin; Vishnu R Mani; Cristina Hajdu; Dannielle Engle; George Miller
Journal:  Nature       Date:  2016-04-06       Impact factor: 49.962

10.  CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation.

Authors:  Jeremy G Price; Juliana Idoyaga; Hélène Salmon; Brandon Hogstad; Carolina L Bigarella; Saghi Ghaffari; Marylene Leboeuf; Miriam Merad
Journal:  Nat Immunol       Date:  2015-09-07       Impact factor: 25.606
View more
  6 in total

Review 1.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences.

Authors:  Florian R Greten; Sergei I Grivennikov
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

2.  Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.

Authors:  Chengqiong Mao; Stacy Yeh; Juan Fu; Mercedes Porosnicu; Alexandra Thomas; Gregory L Kucera; Konstantinos I Votanopoulos; Shaomin Tian; Xin Ming
Journal:  Sci Transl Med       Date:  2022-06-08       Impact factor: 19.319

3.  Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.

Authors:  Hongwei Chen; Xin Luan; Hayley J Paholak; Joseph P Burnett; Nicholas O Stevers; Kanokwan Sansanaphongpricha; Miao He; Alfred E Chang; Qiao Li; Duxin Sun
Journal:  Nanomedicine (Lond)       Date:  2020-01       Impact factor: 5.307

4.  Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations.

Authors:  Victoria S Pelly; Agrin Moeini; Shih-Chieh Chiang; Charlotte R Bell; Eimear Flanagan; Christian P Bromley; Christopher Clark; Charles H Earnshaw; Maria A Koufaki; Eduardo Bonavita; Santiago Zelenay
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

Review 5.  Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).

Authors:  Jorge Augusto Borin Scutti
Journal:  Int J Oncol       Date:  2018-02-23       Impact factor: 5.650

6.  Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer.

Authors:  Ming-Jie Jiang; Yi-Yun Chen; Juan-Juan Dai; Dian-Na Gu; Zhu Mei; Fu-Rao Liu; Qian Huang; Ling Tian
Journal:  Mol Cancer       Date:  2020-03-30       Impact factor: 27.401
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.